DSM-Firmenich AG

DSFIR: XAMS (NLD)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
j$fLOCK|?<<LOCK|$WJ#>Ny

DSM-Firmenich Earnings: Good Start to 2025 Amid Reshaping Portfolio

DSM-Firmenich reported first-quarter 2025 organic sales growth of 8% and EBITDA of EUR 650 million, 40% higher than the prior year. The results include a one-off positive price impact from the vitamin supply disruption. The full-year guidance was confirmed.

Sponsor Center